畢馬威中國:內地生物醫藥市場發展向好 進入全球研發領先梯隊
畢馬威中國副主席吳國強在一個頒獎活動稱,內地生物醫藥科技產業正快速由最具發展潛力的高技術產業向高技術支柱產業發展。隨著人口老齡化持續、大健康消費的不斷升級以及近年來相關醫藥監管新政紅利逐步釋放,內地生物醫藥市場發展整體向好,且高質量發展勢頭日趨明顯。
該行華東及華西區市場部主管合夥人黎志賢表示,自2020年新冠肺炎疫情爆發以來,生物科技創新型企業在疫情防控中起到了中流砥柱的作用。科創板以及港股18A上市企業中有數十家企業在疫苗研製、口服抗疫藥物、抗原試劑、核酸檢測都在諸多領域助力新冠疫情防治工作。此外,體外診斷賽道相關企業也已在核酸檢測以及抗原試劑的研發上對中國在疫情防控過程中的快速響應、精準防控提供了良好的技術依托。
該行生命科學行業主管合夥人于子龍稱,「十四五」規劃將創新作為新發展理念中的重中之重,進一步強化了中國科研領域的頂層規劃。中國在研發管線產品和首發上市新藥的數量方面,對全球的貢獻愈來愈大,成功進入全球研發領先梯隊;同時,醫療器械企業的專業授權數量自2016年以來也穩步增長。在上市後市場准入方面,國家醫保談判週期縮短、窗口增加,愈來愈多的創新藥物可以通過談判方式納入國家醫保目錄,也為創新藥物支付提供了更大的支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.